Press Releases Ipsen

Equities

IPN

FR0010259150

Real-time Euronext Paris Other stock markets 10:11:14 2024-05-06 am EDT			5-day change	1st Jan Change
114.2 ^EUR	-0.26%		+1.51%	+5.84%

May. 02	Ipsen Announces Executive Changes	CI
May. 02	Ipsen: new President for North America	CF

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ipsen appoints Keira Driansky as EVP, President of North America	May. 02	GL
Ipsen : Q1 2024 – sales presentation (1.17 MB)	Apr. 24	PU
Ipsen : Q1 2024 – sales announcement (228.28 KB)	Apr. 24	PU
Ipsen : Q1 2024 – highlights (288.70 KB)	Apr. 24	PU
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance	Apr. 24	GL
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance	Apr. 24	AQ
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases	Apr. 22	GL
Ipsen : 2023 Universal Registration Document	Apr. 18	PU
Ipsen publishes its 2023 Universal Registration Document	Apr. 17	GL
Ipsen publishes its 2023 Universal Registration Document	Apr. 17	AQ
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen	Apr. 03	AQ
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors	Apr. 02	GL
Ipsen S.A. publishes its 2023 Consolidated Financial Statements	Feb. 15	GL
Merrimack Reports Ipsen Announcement of Approval by The US FDA of Onivyde Plus 5 Fluorouracil/Leucovorin and Oxaliplatin as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma	Feb. 14	AQ
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA	Feb. 13	GL
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024	Feb. 08	GL
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024	Feb. 08	AQ
Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024	Jan. 22	GL
Ipsen – Half year statement – 2023 12 31	Jan. 08	GL
Ipsen – Half year statement – 2023 12 31	Jan. 08	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

IPSEN : Better-than-expected Q1; guidance unchanged

April 24, 2024 at 10:50 am EDT